The company will utilize the funds to accelerate its product development plans and increase

its international commercial presence.

Ovizio, a spin-off company of the Université Libre de Bruxelles (ULB), founded by Serge Jooris

(CTO) and Philip Mathuis (CEO) in December 2009 has secured a Series A funding of 5M€ that will

be used to accelerate its product development pipeline and to launch its international expansion.

The company develops a new-patented 3D microscopy technology based on Digital Holography

invented by co-founders Professor Frank Dubois and Dr. Catherine Yourassowsky from the

Université Libre de Bruxelles (ULB). The breakthrough platform is used in life science research,

bioprocessing and diagnostics and has already been adopted by global pharmaceutical and

biotechnology leaders.

Ovizio was launched in December 2009 with seed funding from the founding team, the University’s

Theodorus II fund and the SRIB (Société Régionale d'Investissement de Bruxelles). The company

also received R&D grants from Innoviris, the Brussels Institute for Research and Innovation.

Ovizio, assisted by GoNext, has chosen an entrepreneurial led investor consortium around two

venture funds (Sherpa Invest II – BAMS Angels Fund II) completed with two industrial partners,

private investors and its historical partners.

Philip Mathuis, CEO of Ovizio, said: ”We are very excited to have such an outstanding syndicate of

investors that appreciate and understand the potential of our technology. The financial support that

we have received will allow us to expand our efforts in developing a platform technology and

commercial organization that address unmet needs in our markets.”

Serge Jooris, CTO of Ovizio, said: “This investment will allow us to strengthen our core R&D team

and to focus our efforts on reducing the size and footprint of our technology allowing us to build

products that will help our clients increase their productivity and accelerate their research and

discovery capabilities”.

Jean Van Nuwenborg, Partner of the Theodorus II investment fund, said: “Ovizio combines the key

success factors of any spin-off with global ambitions: outstanding science, an experienced

management team, important and global market needs and solid, added-value financial partners. We

are convinced Ovizio will set the standard for future spin-offs”.